• Home
  • Commercial & Medical
  • Gilead bets $1.68B upfront on Ouro Medicines’ autoimmune program, with Galapagos expected to pitch in

Gilead Sciences is set to join the T-cell engager space in an unusual – perhaps even unprecedented – deal arrangement that involves the pharma budgeting $1.675 billion upfront to buy Ouro Medicines and for Galapagos …

Subscribe for Updates

Copyright 2025 dijee Intelligence Ltd.   dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registration number 16808844